Advertisement

U.S. Markets open in 8 hrs

S&P Futures
3,927.50
+29.75(+0.76%)
Dow Futures
31,392.00
+190.00(+0.61%)
Nasdaq Futures
11,995.75
+117.50(+0.99%)
Russell 2000 Futures
1,792.40
+17.50(+0.99%)
Crude Oil
110.85
-1.36(-1.21%)
Gold
1,842.70
+1.50(+0.08%)

Advertisement

China Literature Limited (CHLLF)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

3.9886

0.0000

(0.00%)

At close: 10:47AM EDT

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Zacks
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Zacks
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Will ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Advertisement